ILMN vs PFE: fair value comparison
Illumina, Inc. and Pfizer Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ILMN currently sits closer to the top of our discount ranking. ILMN carries the stronger quality grade.
| ILMN | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $198.16 | $28.45 |
| 12-month range | $102.26–$198.16 | $24.23–$28.55 |
| Sector rank | #98 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | C | F |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ILMN fair value analysis · PFE fair value analysis